Drug Trial Radar · NCT06246110
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 6, 2024
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Conditions
- NSCLC
Interventions
EIK1001Drug
EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
PembrolizumabDrug
PD-1 inhibitor
PaclitaxelDrug
Chemotherapy
PemetrexedDrug
Chemotherapy
CarboplatinDrug
Chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with safety event during treatmentTime frame: Up to 2 years
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Southern Cancer Care
Daphne, Alabama
Ironwood Cancer and Research Center
Chandler, Arizona
California Cancer Care Associates for Research & Excellence
Fresno, California
California Research Institute
Los Angeles, California
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California
Providence St Joseph Hospital, Center for Cancer Prevention and Treatment
Orange, California
Sutter Health Institute for Medical Research
Sacramento, California
Rocky Mountain Cancer
Lone Tree, Colorado
Bioresearch Partner
Hialeah, Florida
Memorial Cancer Institute
Hollywood, Florida
Mid-Florida Hematology and Oncology Center
Orange, Florida
Orlando Health Cancer Institute
Orlando, Florida
Atlanta Piedmont Hospital
Atlanta, Georgia
Kaiser Permanente Hawaii
Honolulu, Hawaii
Illinois Cancer Specialists
Niles, Illinois
Accelacare of Duly
Tinley Park, Illinois
Indiana University Cancer Center
Indianapolis, Indiana
Health Midwest Oncology Associates of Kansas
Overland Park, Kansas
Cancer Center of Kansas
Wichita, Kansas
Medstar Franklin Square Cancer Center at Loch Raven Campus
Baltimore, Maryland
Maryland Oncology
Columbia, Maryland
Jersey Shore University Medical Center/Meridian Hematology & Oncology
Neptune City, New Jersey
New York Cancer and Blood Specialists
Babylon, New York
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Weil Cornell Medical Center
New York, New York
Albert Einstein College of Medicine, Jacobi Medical Center
The Bronx, New York
Cancer and Blood Specialists of New York, White Plains Hospital
White Plains, New York
Messino Cancer Centers
Asheville, North Carolina
Gabrail Cancer Center
Canton, Ohio
Willamette Valley
Eugene, Oregon
Tennessee Cancer Specialists
Knoxville, Tennessee
Baptist Cancer Center
Memphis, Tennessee
Texas Oncology, Austin
Austin, Texas
Texas Oncology, Bedford
Bedford, Texas
The Center for Cancer and Blood Disorders
Fort Worth, Texas
Blue Ridge Cancer Care Oncology Associates SW VA
Blacksburg, Virginia
Virginia Cancer Specialists
Fairfax, Virginia
Shenandoah Oncology
Winchester, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.